Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2007Journal of Cardiovascular Pharmacology

Fenofibrate treatment blunted the reduction in left ventricular ejection fraction, reduced cardiac hypertrophy, and attenuated clinical signs of heart failure compared to placebo.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does fenofibrate slow down the progression of left ventricular dysfunction in pigs with pacing-induced heart failure?

Population

Pigs with pacing-induced heart failure

Comparison

Fenofibrate (clinically relevant dose) vs Placebo

Design

Preclinical

Authors

FBFrançois BrigadeauPGPatrick GeléMWMaud Wibaux

Discussion

Loading...

Member takes

Overview

Should not change HF practice; leaves open whether benefits extend beyond this pacing-induced pig model.

Structured PICO

Does fenofibrate slow down the progression of left ventricular dysfunction in pigs with pacing-induced heart failure?

P
Population
Pigs with pacing-induced heart failure
I
Intervention
Fenofibrate (clinically relevant dose)
C
Comparator
Placebo
O
Outcome
Progression of left ventricular dysfunction (including left ventricular ejection fraction, cardiac hypertrophy, and clinical signs of heart failure)surrogate

A clinically relevant dose of fenofibrate slows down, rather than accelerates, the development of heart failure in a large mammal model of pacing-induced cardiomyopathy.

Cite This Study

Brigadeau et al. (2007) studied this question.

synapsesocial.com/papers/6a89392a07adfc24ebcaf6fbhttps://doi.org/10.1097/fjc.0b013e3180544540
View Full Paper
Ask AI
Bookmark
Share